GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ValiRx PLC (LSE:VAL) » Definitions » ROIC %

ValiRx (LSE:VAL) ROIC % : -72.14% (As of Jun. 2023)


View and export this data going back to 2000. Start your Free Trial

What is ValiRx ROIC %?

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. ValiRx's annualized return on invested capital (ROIC %) for the quarter that ended in Jun. 2023 was -72.14%.

As of today (2024-04-26), ValiRx's WACC % is -2.15%. ValiRx's ROIC % is -86.55% (calculated using TTM income statement data). ValiRx earns returns that do not match up to its cost of capital. It will destroy value as it grows.


ValiRx ROIC % Historical Data

The historical data trend for ValiRx's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ValiRx ROIC % Chart

ValiRx Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
ROIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -113.70 -67.76 -44.58 -52.21 -84.18

ValiRx Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -50.95 -55.10 -72.35 -102.92 -72.14

Competitive Comparison of ValiRx's ROIC %

For the Biotechnology subindustry, ValiRx's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ValiRx's ROIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ValiRx's ROIC % distribution charts can be found below:

* The bar in red indicates where ValiRx's ROIC % falls into.



ValiRx ROIC % Calculation

ValiRx's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Dec. 2022 is calculated as:

ROIC % (A: Dec. 2022 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2021 ) + Invested Capital (A: Dec. 2022 ))/ count )
=-2.593 * ( 1 - 7.43% )/( (2.909 + 2.794)/ 2 )
=-2.4003401/2.8515
=-84.18 %

where

ValiRx's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Jun. 2023 is calculated as:

ROIC % (Q: Jun. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2022 ) + Invested Capital (Q: Jun. 2023 ))/ count )
=-2.302 * ( 1 - 7.81% )/( (2.794 + 3.09)/ 2 )
=-2.1222138/2.942
=-72.14 %

where

Note: The Operating Income data used here is two times the semi-annual (Jun. 2023) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ValiRx  (LSE:VAL) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, ValiRx's WACC % is -2.15%. ValiRx's ROIC % is -86.55% (calculated using TTM income statement data).


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


ValiRx ROIC % Related Terms

Thank you for viewing the detailed overview of ValiRx's ROIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


ValiRx (LSE:VAL) Business Description

Traded in Other Exchanges
Address
4 Barling Way, Eliot Park Innovation Centre, Nuneaton, GBR, CV10 7RH
ValiRx PLC is a UK-based biopharmaceutical company. It mainly engages in developing technologies and products in oncology therapeutics and diagnostics. The area of focus for the company is the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis. The company develops therapeutics across fields in oncology and has a portfolio of products in the pipeline which include GeneICE for Silencing Rebellious Genes, VAL201 for prostate cancer, NAV3 for the cancer screening test, and VAL401 for lung cancer.

ValiRx (LSE:VAL) Headlines

From GuruFocus

Valaris Provides Fleet Status Report

By Business Wire Business Wire 02-21-2023

Valaris Provides Quarterly Fleet Status Report

By Business Wire Business Wire 10-31-2022

Valaris Announces Contract Award for Drillship VALARIS DS-12

By Business Wire Business Wire 11-21-2022

Valaris Provides Fleet Status Report

By Business Wire 08-02-2023

Valaris Publishes Sustainability Report

By Business Wire Business Wire 12-15-2022

Valaris Announces Contract Awards and Fleet Status Updates

By Business Wire Business Wire 12-16-2022